Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation

Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation

Abstract Diabetes manifests as chronic inflammation and leads to the development diabetic cardiomyopathy (DCM). Targeting key proteins in inflammatory signaling may provide new therapy for DCM. In this study, the authors explore the pharmacological effects and mechanisms of Schisandrin B (Sch B), a...

Full description

Bibliographic Details
Main Authors: Wu Luo, Ke Lin, Junyi Hua, Jibo Han, Qiuyan Zhang, Lingfeng Chen, Zia A. Khan, Gaojun Wu, Yi Wang, Guang Liang
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Advanced Science
Subjects:
cardiomyocytes
diabetic cardiomyopathy
inflammation
MyD88
Schisandrin B
Online Access:https://doi.org/10.1002/advs.202202590

Internet

https://doi.org/10.1002/advs.202202590

Similar Items